Lactose
Migraine Disorder
UNKNOWNPhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
101 Active assets in the Migraine Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atogepant Stanford University | Phase 4 | A |
Rizatriptan Antonios Likourezos | Phase 4 | A |
Zolmitriptan Zosano Pharma Corporation | Phase 4 | A |
Naproxen IRCCS San Raffaele Roma | Phase 4 | A |
Eptinezumab Stanford University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Lactose is also rated in:
metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative · Phase 3
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →